Outlook Therapeutics, Inc.
OTLK · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.09 | 0.04 | 0.37 |
| FCF Yield | -140,521,023.34% | -69.45% | -77.73% | -21.90% |
| EV / EBITDA | 0.12 | -1.58 | -1.18 | -3.92 |
| Quality | ||||
| ROIC | 240.82% | -454.96% | -251.50% | -319.32% |
| Gross Margin | 4.05% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.83 | 0.91 | 0.73 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -75,340,109.88% | -60.08% | 24.18% | -4.46% |
| Safety | ||||
| Net Debt / EBITDA | 0.12 | -0.21 | -0.21 | 0.10 |
| Interest Coverage | -236.86 | -22.71 | -34.06 | -42.41 |
| Efficiency | ||||
| Inventory Turnover | 0.41 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,459.48 | -25,545.50 | -54,306.62 | -6,225.84 |